Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Recent Articles in Week in Review

Week in Review: China Biopharmas Announce Three Out-licensing Deals Totaling $2 Billion
Week in Review: CANbridge In-Licenses Gene Therapy for Rare Disease from UMass
Week in Review: Structure Stages $161 Million US IPO for AI/Structure-based Drug Development
Week in Review: HutchMed Announces $1.1 Billion Deal with Takeda for Colorectal Cancer Drug
Week in Review: Mabwell Out-Licenses Rare Disease Drug for $412.5 Million
ChinaBio Event
Singapore and Digital
April 26-27, 2023
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China